SCHEMBL7223258

SCHEMBL7223258

COc1ccc(NC(=O)c2c[nH]c3c2-c2nn(C)cc2CCC3)c(OC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.39
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
JAK1 P23458 6/20 0.36
BRD4 O60885 1/20 0.34
JAK2 O60674 5/20 0.33
PRKAG1 P54619 1/20 0.33
PRKAA1 Q13131 1/20 0.33
PRKAB1 Q9Y478 1/20 0.33
TYK2 P29597 2/20 0.33
JAK3 P52333 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7221648 0.86 JAK2 (0.40) ALDH1A1RAB9ACSNK1DCSNK1EJAK1
SCHEMBL6834309 0.80 LMNA (0.42) HPGDSMN1; SMN2HSD17B10ALDH1A1HTT
SCHEMBL7216813 0.78 F10 (0.39) RAB9ANPC1
SCHEMBL7216626 0.77 APLNR (0.44) HPGDSMN1; SMN2HTTRAB9ANPC1
SCHEMBL6834487 0.75 GAA (0.43) SMN1; SMN2ALDH1A1HTTRAB9ANPC1
SCHEMBL7217055 0.75 NPC1 (0.48) TSHRSMN1; SMN2HTTRAB9ANPC1
SCHEMBL6831069 0.75 NAMPT (0.53) HPGDTSHRSMN1; SMN2ALDH1A1HTT
SCHEMBL7222852 0.75 NPC1 (0.43) HPGDSMN1; SMN2HSD17B10ALDH1A1RAB9A
SCHEMBL6304803 0.74 DRD4 (0.44) HPGDHSD17B10ALDH1A1DRD4DRD2
SCHEMBL6834466 0.73 KMT2A (0.37) TSHRSMN1; SMN2ALDH1A1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed